GlassScriptPhysician profile
Sierra Presley
NPI 1194399790
$1,276.18
in general payments reported to CMS, 2019-2025
19 companies · $688 in 2025
The $688 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.92 · 2023: $166 · 2024: $376 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $316.18 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $204.80 | 2024-2025 | Korlym |
| Abbvie INC. | $127.33 | 2023-2025 | |
| Pfizer INC. | $126.00 | 2024-2025 | |
| Lilly USA, LLC | $68.29 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $68.26 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $48.83 | 2021-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $43.48 | 2025 | Airsupra, Farxiga |
| Xeris Pharmaceuticals, INC. | $37.70 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.04 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $32.81 | 2023 | Zejula, Jemperli |
| Phathom Pharmaceuticals, INC. | $30.92 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $30.32 | 2025 | |
| Genzyme Corporation | $25.75 | 2025 | |
| Astellas Pharma US INC | $17.25 | 2025 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $16.46 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.41 | 2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $16.35 | 2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sierra Presley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.